



**Supplementary Figure 1. Purity of column-purified CD4+CD25- T cells.**

CD4+CD25- T cell percentage before and after purification with a T cell isolation kit from Miltenyi Biotec. Purified cells were stained with fluochrome-conjugated antibodies against CD11b, CD11c and NK1.1 to analyze the contaminated subsets. According to the cell staining results, CD11b+ cells were the major contaminants (1.83%). (B) Purified CD4+CD25- T cell were cultured under Th1 or Th17 condition in the presence or absence of berberine (5 $\mu$ M) for 4 days and stained with fluochrome-conjugated antibodies against CD11b, CD80 and CD86. Staining with specific antibody to CD80 or CD86 was indicated by open contour and gray contour represents isotype control.




**Supplementary Figure 2. Berberine decreased the ability of inflammatory T cells to transfer diabetes.**

$1.2 \times 10^7$  Naïve CD4<sup>+</sup> T cells were differentiated into Th17 (A) or Th1 (B) in the absence or presence of berberine (5  $\mu$ M) and adoptively transferred into 4 NOD.*scid* mice by i.v. injection. Non-fasting blood glucose was measured weekly for 49 days and it was considered diabetic when the blood glucose was higher than 250 mg/dL .



**Supplementary Figure 3. Berberine did not affect NK, NKT or Treg subsets.**

Splenocytes from vehicle or berberine-treated NOD mice were stained for NK1.1 alone (upper panel), NK1.1 plus CD3 (medium panel) and Foxp3 plus CD4 (lower panel) (Three mice per group).



**Supplementary Figure 4. Cytokine profile of Th1 and Th17 cell culture in the presence of berberine.**

Purified CD4+CD25- T cell were cultured under Th1 or Th17 condition for 4 days in the presence or absence of berberine (5 $\mu$ M) for 4 days and supernatant was collected for cytokine assay by ELISA (\*\*, p<0.01).